Weekly Recap: BTC Phase III OS at ESMO 2026 and ivonescimab China approval

Summit Therapeutics Inc (NASDAQ:SMMT) said Phase III BTC topline data showing overall survival superiority will be presented at ESMO 2026 while the company advances licensed ivonescimab, a dual—action bispecific antibody approved in China but still investigational in its U.S. and EU territories.Pre…